BioDelivery Sciences Earlier Reported Q2 EPS $0.09 Beats $0.05 Estimate, Sales $41.44M Miss $42.41M Estimate
BioDelivery Sciences Intl (NASDAQ:BDSI) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.05 by 80 percent. This is unchanged from the same period last year. The company
BioDelivery Sciences International To Acquire US And Canadian Rights To ELYXYB From Dr. Reddy’s Laboratories For Upfront Payment Of $6M Plus An Additional $9M
The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults
First step to building a growth platform in Neurology
Patent protection until 2036
RALEIGH, N.C.,
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell
• ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.